

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A30; B60, B62; Cw9, Cw10; DR4, DR13; DQ6, DQ8

		Summary of Results							
		PBL/T-Cells				B-Cells			
Total tested		34	34	34	33	24	23	23	23
Positive		0	5	0	24	0	4	2	22
Negative		34	29	34	9	24	19	21	1
NT/Equivocal		3	3	3	4	4	5	5	5
% Positive		0.0%	14.7%	0.0%	72.7%	0.0%	17.4%	8.7%	95.7%
% Negative		100.0%	85.3%	100.0%	27.3%	100.0%	82.6%	91.3%	4.3%
<b>Consensus</b>		<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>
HLA Antibody Specificity (Defined By CDC)		DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52

Lab No.	PBL/T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES	NO	Negative	Negative	Negative	Positive					
119	YES	NO	Negative	Negative	Negative	Positive					
120	YES	YES	Negative	<b>Positive</b>	Negative	Positive	Negative	<b>Positive</b>	Negative	Positive	
128	YES	NO	Negative	Negative	Negative	Positive					
133	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
139	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
143	YES	NO	Negative	Negative	Negative	Positive					
147	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	<b>Positive</b>	Positive	
154	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
157	YES	YES	Negative	Negative	Negative	Positive	Negative	<b>Weak Positive</b>	Negative	Positive	
159	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	<b>Equivocal</b>	
169	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
181	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	<b>Equivocal</b>	Positive	
189	YES	NO	Negative	Negative	Negative	Positive					
190	YES	YES	Negative	<b>Positive</b>	Negative	Negative	Negative	Negative	Negative	Positive	
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
195	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
197	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
209	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
216	YES	NO	Negative	Negative	Negative	Positive					
223	YES	YES	Negative	Negative	Negative	Positive	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	B-cells not tested due to low viability
229	YES	NO	Negative	<b>Positive</b>	Negative	Negative					
232	YES	NO	Negative	Negative	Negative	Positive					
235	YES	NO	Negative	Negative	Negative	Positive					
238	YES	YES	Negative	Negative	Negative	Positive	Negative	<b>Equivocal</b>	<b>Positive</b>	Positive	
245	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
252	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
259	YES	YES	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	Poor cell viability
260	YES	YES	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	Poor cell viability
262	YES	YES	Negative	Negative	Negative	<b>Equivocal</b>	Negative	Negative	Negative	Positive	
292	YES	YES	Negative	<b>Positive</b>	Negative	Negative	Negative	<b>Positive</b>	Negative	<b>Negative</b>	
293	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
294	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
297	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
321	YES	YES	Negative	<b>Positive</b>	Negative	Positive	Negative	<b>Positive</b>	Negative	Positive	
351	YES	YES	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	Poor cell viability

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	1	1	1	8					70		
119	1	1	1	6					95		
120	1	2	1	4	1	2	1	8			
128	1	1	1	6					95		
133	0	0	0	0	0	0	0	8		90	60
139	1	1	1	4	1	1	1	6	80	80	80
143	1	1	1	6					90		
147	1	1	1	6	1	1	4	8		100	100
154	1	1	1	1	1	1	1	6	99	99	99
157	1	1	1	6	1	4	1	8	80	80	80
159	1	1	1	8	1	1	1	1		90	70
169	1	1	1	1	1	1	1	8		98	97
181	1	1	1	6	1	1	2/4	8		99	99
189	1	2	1	6					85		
190	1%	50%	1%	1%	1%	1%	1%	100%		99	99
193	1	1	1	1	1	1	1	4	99	99	99
194								8	100		
195	1	1	1	1	1	1	1	8	80		60
197				Strong				Strong	90	85	85
209	1	1	1	8	1	1	1	8	95		
216	1	1	1	4					90		
223										100	75
229		2							90		
232	0	0	0	4					80		
235	1	1	1	6					85		
238	1	1	1	4	1	2	1	8	95	95	80
245	1	1	1	8	1	1	1	8	100	100	100
252	1	1	1	4	1	1	1	4-6	70		50
259	NT	NT	NT	NT	NT	NT	NT	NT	85	85	85
260	NT	NT	NT	NT	NT	NT	NT	NT		50	50
262								8	100	100	100
292		4				4				98	30
293				4				8		80	80
294	0	0	0	4	0	0	0	8		98	95
297	1	1	1	4	1	1	1	6	90	90	90
321	1	2	1	2	1	2	1	8		98	98
351	NT	NT	NT	NT	NT	NT	NT	NT	<10	<10	<10

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
112	Negative	Negative	Negative	Positive	1	1	1	8	NT	NT	NT	NT	NT	NT	NT	NT
120	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive	1	2	1	4
128	Negative	Negative	Negative	Positive	1	1	1	6	NT	NT	NT	NT	NT	NT	NT	NT
133	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Negative	Positive	-	-	-	1
139	Negative	Negative	Negative	Positive	1	1	1	4	Negative	Negative	Negative	Positive	1	1	1	4
147	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	1	1	1	6
154	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
189	Negative	Negative	Negative	Positive	1	2	1	6	NT	NT	NT	NT	NT	NT	NT	NT
193	Negative	Negative	Negative	Positive	1	1	1	2	Negative	Negative	Negative	Negative	1	1	1	1
232	Negative	Negative	Negative	Positive	0	0	0	4	NT	NT	NT	NT	NT	NT	NT	NT
238	Negative	Negative	Negative	Positive	1	1	1	6	Negative	Negative	Negative	Positive	1	1	1	4
245	Negative	Negative	Negative	Positive	1	1	1	8	Negative	Negative	Negative	Positive	1	1	1	2
262	Negative	Negative	Negative	Equivocal	-	-	-	-	Negative	Negative	Negative	Equivocal	-	-	-	-
292	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	-	4	-	-
293	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	-	-	-	4

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A30; B60, B62; Cw9, Cw10; DR4, DR13; DQ6, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	29	29	29	28	22	22	22	23			
Positive	0	1	0	17	0	0	1	22			
Negative	29	28	29	11	22	22	21	1			
NT/Equivocal	1	1	1	2	2	2	2	1			
% Positive	0.0%	3.4%	0.0%	60.7%	0.0%	0.0%	4.5%	95.7%			
% Negative	100.0%	96.6%	100.0%	39.3%	100.0%	100.0%	95.5%	4.3%			
Consensus	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>			
HLA Antibody Specificity (Defined By CDC)	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52			
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES	NO	Negative	Negative	Negative	Positive					
119	YES	NO	Negative	Negative	Negative	Positive					
120	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
133	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
139	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
143	YES	NO	Negative	Negative	Negative	Positive					
147	YES	YES	Negative	Negative	Negative	Positive					
157	NO	YES					Negative	Negative	<b>Positive</b>	Positive	
159	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
169	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
181	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	<b>Equivocal</b>	Positive	
189	YES	NO	Negative	Negative	Negative	Positive					
190	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
195	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
197	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
209	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
216	YES	NO	Negative	Negative	Negative	Positive					
229	YES	NO	Negative	<b>Positive</b>	Negative	Negative					
235	YES	NO	Negative	Negative	Negative	Positive					
238	YES	YES	Negative	Negative	Negative	Positive	Negative	<b>Equivocal</b>	Negative	Positive	
245	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
252	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
260	YES	YES	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	<b>NT</b>	Poor cell viability
262	YES	YES	Negative	Negative	Negative	<b>Equivocal</b>	Negative	Negative	Negative	Positive	
292	YES	YES	Negative	Negative	Negative	<b>Equivocal</b>	Negative	Negative	Negative	<b>Negative</b>	
293	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
294	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
297	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
321	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	1	1	1	8					70		
119	1	1	1	4					95		
120	1	1	1	1	1	1	1	8			
133	0	0	0	0	0	0	0	8		90	60
139	1	1	1	4	1	1	1	6	80	80	80
143	1	1	1	4						90	
147	1	1	1	6	1	1	4	8		100	100
157					1	1	1	8	80	80	80
159	1	1	1	8	1	1	1	8		90	70
169	1	1	1	1	1	1	1	8		98	97
181	1	1	1	4	1	1	2/4	8		99	99
189	1	2	1	6					85		
190	1%	1%	1%	1%	1%	1%	1%	100%		99	99
193	1	1	1	1	1	1	1	4	99	99	99
194								8	100		
195	1	1	1	1	1	1	1	8	80		60
197				Strong				Strong	90	85	85
209	1	1	1	8	1	1	1	8	95		
216	1	1	1	4					90		
229		2							90		
235	1	1	1	6					85		
238	1	1	1	4	1	2	1	8	95	95	80
245	1	1	1	4	1	1	1	4	100	100	100
252	1	1	1	4	1	1	1	4-6	70		50
260	NT	NT	NT	NT	NT	NT	NT	NT		50	50
262								8	100	100	100
292										98	30
293				6				8		80	80
294	0	0	0	2	0	0	0	8		98	95
297	1	1	1	4	1	1	1	6	90	90	90
321	1	1	1	1	1	1	1	8		98	98

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
112	Negative	Negative	Negative	Positive	1	1	1	8	NT	NT	NT	NT	NT	NT	NT	NT
120	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
128	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
133	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Negative	Positive	-	-	-	1
139	Negative	Negative	Negative	Positive	1	1	1	4	Negative	Negative	Negative	Positive	1	1	1	4
147	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	1	1	1	6
154	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
189	Negative	Negative	Negative	Positive	1	2	1	6	NT	NT	NT	NT	NT	NT	NT	NT
193	Negative	Negative	Negative	Positive	1	1	1	2	Negative	Negative	Negative	Negative	1	1	1	1
232	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
238	Negative	Negative	Negative	Positive	1	1	1	6	Negative	Negative	Negative	Positive	1	1	1	4
245	Negative	Negative	Negative	Positive	1	1	1	4	Negative	Negative	Negative	Positive	1	1	1	2
262	Negative	Negative	Negative	Equivocal	-	-	-	-	Negative	Negative	Negative	Equivocal	-	-	-	-
292	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	-	-	-	-
293	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	-	-	-	6